FDA approves Bayer’s Ultravist (iopromide) injection for contrast-enhanced mammography


23 June 2023 - Ultravist-300, -370 is now the only contrast agent in the US indicated to visualise known or suspected lesions of the breast in adults, as an adjunct to mammography and/or ultrasound.

Bayer announced today that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved by the US FDA for contrast-enhanced mammography – making it the only contrast agent approved for this indication.

Read Bayer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Diagnostic agent , FDA